肿瘤防治研究2026，Vol.53Issue(5)：325-331,7.DOI:10.3971/j.issn.1000-8578.2026.26.0012
OptiTROP-Lung04研究在EGFR-TKI耐药非小细胞肺癌中的创新价值与临床启示
Innovative Value and Clinical Implications of OptiTROP-Lung04 Study in EGFR-TKI-Resistant Non-Small Cell Lung Cancer
摘要
Abstract
Antibody-drug conjugates(ADCs)have emerged as a standard treatment modality for previously treated driver gene-positive advanced non-small cell lung cancer(NSCLC).Sacituzumab tirumotecan(sac-TMT),a novel TROP-2-targeting ADC,has been the focus of the phase Ⅲ clinical trial OptiTROP-Lung04.This trial demonstrated,for the first time,that single-agent sac-TMT significantly improves progression-free survival and overall survival compared with conv-entional platinum-based chemotherapy in patients with epidermal growth factor receptor(EGFR)mutant advanced NSCLC following resistance to EGFR tyrosine kinase inhibitors.This review combines existing consensus from lit-erature with the latest research evidence to systematically analyze OptiTROP-Lung04 from multiple perspectives,including molecular mechanisms,study design,clinical significance,and safety management.Furthermore,it explores future development directions in an effort to provide new insights into precision therapy for advanced NSCLC.关键词
非小细胞肺癌/抗体偶联药物/人滋养层细胞表面抗原2Key words
Non-small cell lung cancer/Antibody-drug conjugate/TROP-2分类
医药卫生引用本文复制引用
谭左源,钟雨玲,王婧怡,邬麟..OptiTROP-Lung04研究在EGFR-TKI耐药非小细胞肺癌中的创新价值与临床启示[J].肿瘤防治研究,2026,53(5):325-331,7.基金项目
国家临床重点专科科研专项(Z2023098) （Z2023098）
湖南省卫生健康高层次人才重大科研专项(R2023125) （R2023125）
湖南省科技创新计划(2023SK4024) （2023SK4024）
湖南省肿瘤医院"科研攀登计划"(ZX2020005-5) National Key Clinical Specialty Scientific Research Project(No.Z2023098) （ZX2020005-5）
Hunan Provincial Health High-level Talent Scientific Research Project(No.R2023125) （No.R2023125）
Science and Technology Innovation Program of Hunan Province(No.2023SK4024) （No.2023SK4024）
Hunan Cancer Hospital Climb Plan(No.ZX2020005-5) （No.ZX2020005-5）
